Abvc Biopharma Stock Probability Of Bankruptcy
| ABVC Stock | USD 0.69 0.11 13.75% |
ABVC |
ABVC Biopharma Company probability of distress Analysis
ABVC Biopharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current ABVC Biopharma Probability Of Bankruptcy | Over 71% |
Most of ABVC Biopharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ABVC Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of ABVC Biopharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting ABVC Biopharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of ABVC Biopharma financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, ABVC Biopharma has a Probability Of Bankruptcy of 71%. This is 64.01% higher than that of the Biotechnology sector and 29.47% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 78.26% lower than that of the firm.
ABVC Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ABVC Biopharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ABVC Biopharma could also be used in its relative valuation, which is a method of valuing ABVC Biopharma by comparing valuation metrics of similar companies.ABVC Biopharma is currently under evaluation in probability of bankruptcy category among its peers.
ABVC Fundamentals
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 21.02 M | ||||
| Shares Outstanding | 23.69 M | ||||
| Shares Owned By Insiders | 21.90 % | ||||
| Shares Owned By Institutions | 4.69 % | ||||
| Number Of Shares Shorted | 257.94 K | ||||
| Price To Book | 2.26 X | ||||
| Price To Sales | 32.07 X | ||||
| Revenue | 152.43 K | ||||
| Gross Profit | 369.82 K | ||||
| EBITDA | (8.13 M) | ||||
| Net Income | (10.52 M) | ||||
| Cash And Equivalents | 2.99 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 2.28 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.70 X | ||||
| Cash Flow From Operations | (4.24 M) | ||||
| Short Ratio | 2.49 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 2.02 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 16.35 M | ||||
| Total Asset | 14.49 M | ||||
| Retained Earnings | (65.42 M) | ||||
| Working Capital | (4.28 M) | ||||
| Net Asset | 14.49 M |
About ABVC Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABVC Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABVC Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABVC Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out ABVC Biopharma Piotroski F Score and ABVC Biopharma Altman Z Score analysis. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.